Today: March 24, 2017, 9:05 am

Now Available: Investigation Report on China Enoxaparin Sodium Market, 2009-2018

Fast Market Research recommends "Investigation Report on China Enoxaparin Sodium Market, 2009-2018" from CRI, now available 2014-03-11 15:14:18
Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.

Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.

Full Report Details at
- ..

Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.

Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to CRI's market investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.

The CAGR of sales value of enoxaparin sodium injection in Chinese sample hospitals exceeded 17% from 2005 to 2012. On the one hand, incidence of vascular embolism keeps rising due to population aging in China. On the other hand, operations such as cardiovascular and cerebrovascular intervention develop rapidly. Followed up by the development of anticoagulation, antiplatelet and hypolipidemic treatment after stent surgery, antithrombotic drug market has been greatly expanded in China.

It is estimated that enoxaparin sodium market in China will rise significantly in the next few years.
Through this report, the readers can acquire the following information:

* Incidence of Thrombosis in China
* Market Share of Major Enoxaparin Sodium Manufacturers in China Sample Hospitals
* Sales price of Enoxaparin Sodium in China Hospital Market
* Production Status of Enoxaparin Sodium Generic Drug in China
* Major Enoxaparin Sodium Manufacturers in China
* Prospect of China Enoxaparin Sodium Market

The following enterprises and people are recommended to purchase this report:

* Anti-clotting Drugs Manufacturers
* Medical Institutions
* Investors /Research Agencies Focusing on Anti-clotting Drug Market

About CRI

CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 718 Words
Related Articles
More From Health
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo [..]
PromarkerD Predictive Diagnostics for DKD to Roll-out [..]
PERTH, AUSTRALIA, Mar 22, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader [..]
Do Prostalgene Drops Help To Restore Prostate [..]
Prostate enlargement is among the most common health problems for men over 50. With age the incidence of this condition [..]
Is OnycoSolve Spray The Key To Obliterating [..]
Toenail fungus is an undesirable but stubborn infection that comes with sweating, itching, cracking and scaling of the feet, inflammations, [..]
New Research reveals Asia poised as Preferred [..]
SYDNEY, Mar 10, 2017 - (ACN Newswire) - Frost & Sullivan has released its latest white paper, 'Asia: Preferred Destination for [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.